Russell Investments Group Ltd. raised its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 18.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 322,224 shares of the medical research company's stock after buying an additional 51,144 shares during the quarter. Russell Investments Group Ltd. owned about 0.11% of Agilent Technologies worth $43,289,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also made changes to their positions in the company. Flynn Zito Capital Management LLC increased its stake in Agilent Technologies by 3.8% in the 4th quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company's stock valued at $251,000 after purchasing an additional 69 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Agilent Technologies by 17.7% during the 4th quarter. IFP Advisors Inc now owns 458 shares of the medical research company's stock worth $62,000 after acquiring an additional 69 shares during the period. Tiemann Investment Advisors LLC raised its stake in Agilent Technologies by 5.6% during the fourth quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company's stock worth $191,000 after purchasing an additional 75 shares during the period. Rothschild Investment LLC raised its position in shares of Agilent Technologies by 19.2% in the 4th quarter. Rothschild Investment LLC now owns 491 shares of the medical research company's stock worth $66,000 after buying an additional 79 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its stake in shares of Agilent Technologies by 1.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 7,479 shares of the medical research company's stock valued at $1,025,000 after purchasing an additional 87 shares in the last quarter.
Agilent Technologies Price Performance
Shares of NYSE:A traded up $2.71 on Friday, reaching $102.66. 2,848,584 shares of the company traded hands, compared to its average volume of 1,858,598. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $155.35. The stock has a market capitalization of $29.27 billion, a PE ratio of 23.60, a P/E/G ratio of 2.88 and a beta of 1.19. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. The company's 50 day moving average is $123.76 and its 200-day moving average is $133.84.
Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The business had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. As a group, analysts anticipate that Agilent Technologies, Inc. will post 5.55 earnings per share for the current fiscal year.
Agilent Technologies Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be issued a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.97%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies's dividend payout ratio is currently 22.76%.
Insider Buying and Selling at Agilent Technologies
In other news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total value of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares in the company, valued at approximately $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Daniel K. Podolsky sold 1,819 shares of Agilent Technologies stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the completion of the transaction, the director now directly owns 35,737 shares in the company, valued at approximately $4,161,931.02. This represents a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,638 shares of company stock worth $731,229 over the last 90 days.
Analysts Set New Price Targets
A number of research analysts have commented on A shares. Barclays reduced their price objective on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a research note on Thursday. TD Cowen lifted their target price on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Thursday. Citigroup boosted their price objective on shares of Agilent Technologies to $165.00 and gave the company a "buy" rating in a research report on Thursday, December 19th. StockNews.com upgraded Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. Finally, Robert W. Baird dropped their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $146.25.
View Our Latest Report on A
Agilent Technologies Company Profile
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
